Meet IAG’s Bio-Partnering Team at Sachs Autumn Life Sciences Week
IAG’s team will be attending Sachs Autumn Life Sciences Week, which will start on Monday, the 4th of October (for meetings) and will incorporate the 8th Annual HealthTech Investment Forum (HTIF) and the 21st Annual Biotech in Europe Forum (BEF).
Our team is looking to meet clinical stage biotech companies developing novel treatments to address patients’ needs.
IAG’s Bio-Partnering team is focused on building a diversified portfolio of innovative life science companies at various stages of clinical development.
‘At IAG, by bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry’, said Yeda Ford, IAG’s Chief Business Officer.
Collaboratively, with the best academics of our time we are building mechanisms for early visibility of study performance through our DYNAMIKA platform. When needed and at the right time, our venture partners and analysts support development of the tailored strategies for potential M&As.
‘Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models’, added Dr. Olga Kubassova, AIG’s CEO.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: https://www.ia-grp.com/trial-solutions/bio-partnering/
IAG, Image Analysis Group is unique partner to life sciences companies. We leverage our core expertise in medical image analysis, drug development and trial design. We support investors and biotech executive teams with deploying strategies for early drug efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. Our Bio-partnering team takes a broader view on the assets’ development and helps to bring our R&D solutions, operational breadth, radiological expertise and deploy these via risk-sharing financing and partnership models. www.ia-grp.com
Engage with our team
Dr. Olga Kubassova, CEO: https://www.linkedin.com/in/olgakubassova/
Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer: https://www.linkedin.com/in/dianaroettger/
Schedule call / meeting: email@example.com